MX2023004034A - Métodos de tratamiento de la dermatomiositis. - Google Patents

Métodos de tratamiento de la dermatomiositis.

Info

Publication number
MX2023004034A
MX2023004034A MX2023004034A MX2023004034A MX2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A
Authority
MX
Mexico
Prior art keywords
methods
dermatomyositis
treating
treating dermatomyositis
composition
Prior art date
Application number
MX2023004034A
Other languages
English (en)
Spanish (es)
Inventor
Paul P Tamburini
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023004034A publication Critical patent/MX2023004034A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MX2023004034A 2020-10-05 2021-10-05 Métodos de tratamiento de la dermatomiositis. MX2023004034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087577P 2020-10-05 2020-10-05
PCT/US2021/053540 WO2022076388A1 (en) 2020-10-05 2021-10-05 Methods of treating dermatomyositis

Publications (1)

Publication Number Publication Date
MX2023004034A true MX2023004034A (es) 2023-06-09

Family

ID=81126239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004034A MX2023004034A (es) 2020-10-05 2021-10-05 Métodos de tratamiento de la dermatomiositis.

Country Status (10)

Country Link
US (1) US20230357442A1 (enExample)
EP (1) EP4225372A4 (enExample)
JP (1) JP2023544409A (enExample)
KR (1) KR20230084210A (enExample)
CN (1) CN116472065A (enExample)
AU (1) AU2021358027A1 (enExample)
CA (1) CA3172994A1 (enExample)
IL (1) IL301713A (enExample)
MX (1) MX2023004034A (enExample)
WO (1) WO2022076388A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250030978A (ko) * 2022-06-03 2025-03-05 알렉시온 파마슈티칼스, 인코포레이티드 중증 근무력증의 치료를 위한 융합 폴리펩티드의 투여량 및 투여
CN116313071B (zh) * 2023-01-16 2023-09-08 南方医科大学南方医院 一种预测初诊皮肌炎患者发生快速进展型间质性肺病的风险模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794359A (en) * 1953-09-22 1957-06-04 Lyman Gun Sight Corp Automatic primer feed device
KR102071212B1 (ko) * 2010-04-21 2020-01-30 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
KR102149028B1 (ko) * 2012-02-20 2020-08-27 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 폴리펩티드
US10531135B2 (en) * 2016-01-04 2020-01-07 Telefonaktiebolaget Lm Ericsson (Publ) Network recording apparatus
IL307197B2 (en) * 2017-07-11 2026-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
MX2021011507A (es) * 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
AU2022283254A1 (en) * 2021-05-25 2023-11-30 Alexion Pharmaceuticals, Inc. Kidney active fusion proteins and methods of treatment using the same
WO2023023220A1 (en) * 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor

Also Published As

Publication number Publication date
WO2022076388A1 (en) 2022-04-14
US20230357442A1 (en) 2023-11-09
JP2023544409A (ja) 2023-10-23
EP4225372A4 (en) 2024-11-06
CA3172994A1 (en) 2022-04-14
KR20230084210A (ko) 2023-06-12
AU2021358027A1 (en) 2023-05-11
CN116472065A (zh) 2023-07-21
EP4225372A1 (en) 2023-08-16
IL301713A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
JOP20200309A1 (ar) أجسام مضادة لـ il-11
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX392869B (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico
EP4338804A3 (en) Epinephrine spray formulations
SA523440622B1 (ar) أجسام مضادة
CR20200088A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
PH12022550130A1 (en) Enzyme inhibitors
MX2020011817A (es) Metodos para tratar el linfoma.
PH12022551035A1 (en) Siglec-9 ecd fusion molecules and methods of use thereof
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2021012977A (es) Tratamiento del cáncer con tg02.
WO2018189661A3 (en) Methods and compounds for treating diabetes
PH12020550340A1 (en) Anti-pacap antibody
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
MX2024001211A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre.
MX2022000811A (es) Inhibidores de enzimas.
MX2022004755A (es) Inyector intravitreo.
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
EA202090558A1 (ru) Схемы лечения